Champions Biotechnology wins new US patent for cancer drug

Champions Biotechnology, a US-based drug development company, has reported that the US Patent and Trademark Office has issued a patent for the company's tubulin inhibitors, including its lead compound SG410.

This new US patent protects the company's composition of matter, pharmaceutical composition, and method of treatment for SG410. The patent is owned by Champions Biotechnology.

According to Champions Biotechnology, SG410 is an antimitotic inhibitor that was shown in Tumorgraft models to target microtubule associated protein tau (MAPT) deficient tumors with promising results as compared to a currently marketed and leading chemotherapeutic drug. These antimitotic inhibitors target MAPT deficient tumors. In both in vitro and in vivo models, SG410 has demonstrated promising activity against prostate and pancreatic cancer.

Doug Burkett, president of Champions Biotechnology, said: "This patent solidifies Champions's intellectual property position on SG410. We believe that SG410, in the new Neowater formulation we developed, has the potential to significantly impact the treatment of cancer. SG410 is Champions's first internal compound and is currently undergoing Biomerk Tumorgraft evaluation."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: biotechnology, cancer, patent, pharmaceuticals, president, property